Phase II Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising PSA on Hormone Therapy.
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Erlotinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jun 2011 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.